Want to see IN:JUBLPHARMA full AI Analyst Report?
Jubilant Pharmova Limited (JUBLPHARMA) AI Stock Analysis
Jubilant Pharmova Limited
(NSE:JUBLPHARMA)
The score is primarily held back by inconsistent profitability and especially unreliable free cash flow, despite steady revenue growth and manageable (but rising) leverage. Technicals are bearish with price below key moving averages and negative MACD, while valuation is expensive (high P/E and low yield), limiting upside unless margins and cash generation improve.
Jubilant Pharmova Limited (JUBLPHARMA) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 149.95B
- Dividend Yield
- 0.53%
- Average Volume (3M)
- 37.61K
- Price to Earnings (P/E)
- 42.2
- Beta (1Y)
- 0.73
- Revenue Growth
- 16.27%
- EPS Growth
- -23.50%
- Country
- India
- Employees
- 6,386
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Jubilant Pharmova Limited Business Overview & Revenue Model
Company Description
Jubilant Pharmova Limited functions as a comprehensive pharmaceutical enterprise with a global footprint, structured into three primary divisions: Pharmaceuticals; Contract Research & Development Services; and Proprietary Novel Drugs. The Pharmaceuti...
How the Company Makes Money
Jubilant Pharmova makes money primarily by selling products and services across multiple life-sciences businesses. A major revenue stream comes from contract development and manufacturing (CDMO) and related services, where the company earns fees and...
Jubilant Pharmova Limited Financial Statement Overview
Summary
Steady revenue growth (accelerating to ~8.7% in FY2026) is offset by volatile profitability and a sharp FY2026 gross-margin step-down. Balance sheet leverage is moderate but trending higher in FY2026. Most importantly, free cash flow has been erratic and negative in FY2025–FY2026, indicating weak cash conversion versus earnings.
Income Statement
62PositiveBalance Sheet
58NeutralCash Flow
45Neutral| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 86.08B | 82.80B | 72.34B | 67.03B | 62.82B | 61.30B |
| Gross Profit | 25.01B | 24.94B | 46.99B | 43.52B | 42.00B | 46.42B |
| EBITDA | 12.13B | 12.66B | 11.72B | 9.05B | 9.29B | 12.22B |
| Net Income | 3.52B | 3.98B | 8.39B | 771.00M | -610.00M | 4.14B |
Balance Sheet | ||||||
| Total Assets | 0 | 155.23B | 127.56B | 115.48B | 111.57B | 99.91B |
| Cash, Cash Equivalents and Short-Term Investments | 12.67B | 12.68B | 10.89B | 9.56B | 10.15B | 9.86B |
| Total Debt | 0 | 36.15B | 27.31B | 36.64B | 36.77B | 31.92B |
| Total Liabilities | -70.96B | 84.27B | 65.18B | 61.27B | 57.65B | 46.74B |
| Stockholders Equity | 70.96B | 70.93B | 62.55B | 54.34B | 53.99B | 53.19B |
Cash Flow | ||||||
| Free Cash Flow | -3.71B | -4.36B | -435.00M | 736.00M | -1.54B | 2.38B |
| Operating Cash Flow | 3.69B | 10.13B | 10.72B | 9.71B | 6.61B | 8.38B |
| Investing Cash Flow | -6.31B | -12.85B | 4.88B | -6.08B | -5.44B | -3.80B |
| Financing Cash Flow | -1.84B | 3.33B | -14.53B | -4.33B | -1.57B | -325.99M |
Jubilant Pharmova Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JUBLPHARMA, the sentiment is Negative. The current price of 939.45 is below the 20-day moving average (MA) of 941.13, below the 50-day MA of 966.62, and below the 200-day MA of 940.51, indicating a bearish trend. The MACD of -10.81 indicates Negative momentum. The RSI at 44.70 is Neutral, neither overbought nor oversold. The STOCH value of 67.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:JUBLPHARMA.
Jubilant Pharmova Limited Peers Comparison
Overall Rating
IN:ALIVUS86Outperform
IN:STAR74Outperform
IN:NEULANDLAB66Neutral
IN:GRANULES64Neutral
IN:WOCKPHARMA57Neutral- IN:JUBLPHARMA51Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| IN:ALIVUS | 86Outperform | INR 181.73B | 27.88 | ― | 0.33% | 8.19% | 26.12% |
| IN:STAR | 74Outperform | INR 95.79B | 15.17 | ― | 0.49% | 11.28% | 55.18% |
| IN:NEULANDLAB | 66Neutral | INR 249.35B | 55.50 | ― | 0.17% | 50.46% | 88.44% |
| IN:GRANULES | 64Neutral | INR 197.69B | 27.49 | ― | 0.22% | 21.75% | 36.70% |
| IN:WOCKPHARMA | 57Neutral | INR 303.58B | 75.30 | ― | ― | 25.70% | ― |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| IN:JUBLPHARMA | 51Neutral | INR 149.49B | 42.24 | ― | 0.53% | 16.27% | -23.50% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:JUBLPHARMA | Jubilant Pharmova Limited | 939.45 | -215.92 | -18.69% | |
| IN:ALIVUS | Glenmark Life Sciences Limited | 1520.90 | 632.43 | 71.18% | |
| IN:GRANULES | Granules India Limited | 794.55 | 244.05 | 44.33% | |
| IN:NEULANDLAB | Neuland Laboratories Ltd. | 19614.30 | 2093.84 | 11.95% | |
| IN:STAR | Strides Pharma Science Ltd | 1011.90 | 56.67 | 5.93% | |
| IN:WOCKPHARMA | Wockhardt Limited | 1899.80 | 548.15 | 40.55% |
Jubilant Pharmova Limited Corporate Events
Jubilant Pharmova to Double RUBY-FILL Capacity with CAD 94.5 Million Québec Expansion
Jubilant Pharmova’s radiopharmaceutical arm, Jubilant Draximage Inc., will invest CAD 94.5 million to modernize and expand its Kirkland, Québec facility, doubling production capacity for its flagship RUBY-FILL product and boosting output a...
Jubilant Pharmova Opens Special Window for Physical Share Transfers and KYC Update
Jubilant Pharmova has notified stock exchanges that it has published newspaper advertisements informing shareholders about a special window for re-lodgement of transfer requests for physical shares. The company is also urging investors to update thei...
Jubilant Pharmova Wins USFDA Nod for New Spokane Fill-and-Finish Line
Jubilant Pharmova Limited announced that the U.S. Food and Drug Administration has approved commercial batch manufacturing of the first product on Line 3, a new isolator-based fill-and-finish line at subsidiary Jubilant HollisterStier’s contrac...
Jubilant Pharmova Publishes AGM, E-Voting and Dividend Notice
Jubilant Pharmova Limited operates in the pharmaceutical and life sciences sector, offering a range of healthcare and related products and services. The company is listed on BSE and the National Stock Exchange of India under the symbol JUBLPHARMA, re...
Jubilant Pharmova Updates Shareholders on AGM, Annual Report Access
Jubilant Pharmova has informed exchanges that it has dispatched physical letters to shareholders whose email IDs are not registered, directing them to web links where the company’s FY 2025-26 annual report, TDS communication, and notice of its...
Jubilant Pharmova Sets Final Dividend and Details TDS Rules for Shareholders
Jubilant Pharmova has informed shareholders that its board has recommended a final dividend of ₹5 per equity share for the financial year ended March 31, 2026, payable to investors on record as of July 24, 2026, subject to approval at the upcom...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 25, 2026